SEHK:6660Biotechs
AIM Vaccine (SEHK:6660) Losses Persist In H1 FY 2025 Challenging Bullish Growth Narratives
AIM Vaccine (SEHK:6660) has posted its FY 2025 first half numbers with revenue of C¥514.7 million and a basic EPS loss of C¥0.11, set against prior half yearly revenues of C¥537.2 million and C¥747.9 million with basic EPS losses of C¥0.11 and C¥0.11 respectively. Over the trailing twelve months, revenue has ranged between C¥1.17 billion and C¥1.29 billion while basic EPS has sat between a loss of C¥0.22 and a loss of C¥0.55. Investors now have to judge a business that pairs robust top line...